Medicare AdvantageCoverageMedium impact
MA08.062k, Carfilzomib (Kyprolis®)
Independence Blue Cross·Oncology, Hematology·Pharmacy
Effective date
Nov 17, 2025
We identified it
Jun 19, 2026
Summary
Medicare Advantage updated their policy for Carfilzomib (Kyprolis®), a cancer medication, changing both medical necessity criteria and medical coding requirements. This affects how the drug must be justified and billed for Medicare Advantage patients.
Action Required
By November 17, 2025: Billing team and providers must review updated medical necessity criteria for Carfilzomib (Kyprolis®) prescriptions for Medicare Advantage patients. Update documentation requirements and verify any coding changes in billing system. Oncology providers should ensure proper justification is documented before prescribing.